Impact Therapeutics(07630.HK): Included as a Constituent Stock of Hang Seng Composite Index

NewTimeSpace News: On August 24, 2026, Impact Therapeutics(07630.HK) announced that the Company has been selected by Hang Seng Indexes Company Limited to be a constituent stock of the Hang Seng Composite Index, effective September 7, 2026. Impact Therapeutics stated that upon inclusion, the Company’s shares are expected to qualify for trading under the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programmes. This will help boost trading liquidity, expand and diversify its shareholder base, and support sustainable long-term growth.

According to the announcement, founded in 2009, Impact Therapeutics is a commercial-stage biotechnology firm focusing on precision anti-cancer therapies based on synthetic lethality mechanisms. Its core product pipeline comprises PARP1/2 inhibitors, PARP1 selective inhibitors, ATR inhibitors, WEE1 inhibitors and others.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.